Beta Pharma, Inc.

DUBLIN--( BUSINESS WIRE )--The "State of the Biopharmaceutical Industry 2023" report has been added to ResearchAndMarkets.com's offering. In this report, the publisher examines the business environment and trends that are going to shape the biopharmaceutical industry in 2023. The report highlights the most impactful emerging technologies, industry trends, regulatory trends, and microeconomic factors that are going to impact and dominate the industry throughout 2023. Synopsis The pharmaceutical industry is set to face new challenges such as inflation in a post-COVID-19 world. Genomics, RWE, and IO will dominate as the most impactful trends in the biopharmaceutical industry next year. Among the most impactful trends, genomics will be the key focus in 2023. Inflation and drug pricing pressures will be the top hindrances for pharmaceutical sector growth. Vertical integration, patent expiry of biologics, mega M&As, and ESG factors are anticipated to have the greatest positive impact on the pharmaceutical industry. Big data and AI will continue to dominate as transformational forces in the healthcare sector in 2023. Across the entire value chain, supply chains and manufacturing will be impacted the most by inflation in 2023. The biopharmaceutical industry is less optimistic about industry growth in the next 12 months compared to previous years. The pharmaceutical industry will continue to pursue its efforts to become more sustainable, with more companies committing to ESG strategies. Oncology, CNS, and infectious diseases will be the dominant areas for clinical trials initiated in 2023. Despite political rhetoric, COVID-19-induced pharmaceutical onshoring may not happen. While already met with skepticism by pharma, the Inflation Reduction Act will have to show if it can live up to its name. Key Highlights In 2023, economies and industries will continue to deal with inflationary pressures. Inflation will disrupt pharmaceutical manufacturing and supply chains. Genomics is the trend that will continue to have the greatest impact on the pharmaceutical industry in 2023. Inflation together with drug pricing and reimbursement-related concerns will be the leading impediment to industry growth. Vertical integration, patent expiry of biologics, mega M&As, and ESG factors will have the most positive impacts on industry. While less than in previous years, the biopharmaceutical industry is still optimistic about its growth in 2023. Scope Benchmark the impact of major themes on the biopharmaceutical industry in 2023, including: emerging technologies, regulatory trends, macroeconomic trends, industry trends. Identify themes that will have the greatest positive or negative impact in 2023. Capture opinions on these themes from industry respondents. Assess the impact of COVID-19 on the biopharmaceutical sector. Explore how inflation will affect the pharmaceutical industry in 2023. Reasons to Buy Stay up to date with the major emerging technologies, regulatory, macroeconomic, and industry trends that will impact the pharmaceutical industry in 2023. Explore how the biopharmaceutical landscape has changed. Identify the most impactful anticipated regulatory approvals and drug launches in the industry in 2023. Gain insight into the regulatory and microeconomics trends that will have positive and negative effects on the biopharmaceutical industry. Identify emerging industry trends and innovations to gain a competitive advantage. A selection of companies mentioned in this report includes AbbVie Acceleron Pharma Atara Biotherapeutics Beta Pharma BioMarin Pharmaceutical BioNTech Bio-Thera Solutions Boehringer Ingelheim Bristol-Myers Squibb Catalent Celerity Pharmaceuticals Celltrion Coherus BioSciences CSL Behring CStone Pharmaceuticals CVS Health Corp EirGenix Eli Lilly Exelead Exscientia Ferring Pharmaceuticals Fuji Pharma GSK Immunocore Insud Pharma InventisBio Johnson & Johnson Johnson Matthey Legend Biotech Loxo Oncology Medicaid Health Plans of America Merck Merck & Co Metrics Contract Services Midas Pharma Mirati Therapeutics National Institute for Health and Care Excellence Nippon Kayaku Novartis Ono Pharmaceutical Optum Organon OS Therapies PTC Therapeutics Regeneron Pharmaceuticals Samsung Bioepis Sandoz Sarepta Therapeutics Shanghai Junshi Bioscience Sino Biopharmaceutical Stada Arzneimittel Stelis Biopharma Sumitomo Dainippon Pharma Oncology Teva Pharmaceutical Industries TRACON Pharmaceuticals UnitedHealth Group Veranova Xbrane Biopharma For more information about this report visit https://www.researchandmarkets.com/r/fix73o About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

DUBLIN , Aug. 24, 2022 /PRNewswire/ -- The "Global CD47 Inhibitor Drug Clinical Trials Insight 2028" report has been added to ResearchAndMarkets.com's offering. The global CD47 market opportunity is expected to surpass US$ 2 Billion by 2028 This is mainly due to large number of clinical pipeline products which are expected to gain approval and their encouraging response in the management of cancer. Further, the huge investments by pharmaceutical giants and special designations also suggest the promising growth of the market. Immunotherapy particularly with immune checkpoint inhibitors has shown to transform the global cancer therapeutics market. However, despite these huge advancements in the field of cancer therapeutics, the majority of patients does not respond to or develop resistance to immunotherapy, highlighting the need for additional approaches to expand cancer immunotherapy. In the last few years, technological advancements have enabled the identification of various other receptors which can be of therapeutic potential. Recently, CD47 has gained the major focus of researchers as a therapeutic potential target for drug development. Till date, no CD47 targeting antibody has gained market authorization. However, the pipeline is highly crowded indicating encouraging role of CD47 targeting therapies in the management of cancer. Magrolimab developed by GlaxoSmithKline is one of the most promising CD47 targeting antibodies in clinical development. Currently, the company is evaluating the drug in a phase-III clinical trial accessing the efficacy and safety of Magrolimab in combination with azacitidine for the management of acute myeloid leukemia and myelodysplastic syndrome. The drug has received fast-track designation from US FDA and is expected to enter the market by 2024. Apart from this, several other pharmaceutical giants have developed a robust clinical pipeline of the CD47 targeting therapies which are being evaluated in various phase-I/II clinical trials. The companies have also adopted strategic alliances such as collaboration, partnership, or acquisitions to maintain their competitive edge in the market. For instance, AbbVie entered into collaboration with I-Mab for the development and commercialization of lemzoparlimab (also known as TJC4), an innovative anti-CD47 monoclonal antibody internally discovered and developed by I-Mab for the treatment of multiple cancers. In addition, the two partners have the potential to expand the collaboration to additional transformative therapies. To further enhance the therapeutic potential of CD47 targeting therapies, researchers have also initiated clinical trials evaluating their role in combination therapies. For instance, Arch Oncology and Merck are currently conducting phase-I/II clinical trial to evaluate AO-176, the Company's novel anti-CD47 antibody in combination with Keytruda for the treatment of patients with select solid tumors including relapsed, platinum-resistant ovarian cancer, endometrial cancer, and gastroesophageal cancer. Another, ALX Oncology in collaboration with Eli Lilly to evaluate the combination of ALX148, a next-generation CD47 blocker, and Cyramza for the treatment of patients with HER2-positive gastric cancer or gastroesophageal junction cancer. It is suggested that combination therapies will dominate the global market owing to their enhanced efficacy and specificity towards cancer cells. US and Chinese pharmaceutical firms are currently dominating the CD47 inhibitors drugs RandD landscape driven by encouraging clinical pipeline, increasing cancer research activities to find innovative therapies, and favorable government policy framework. For instance, in 2022, US FDA granted orphan drug designation to AO-176 for the management of relapsed or refractory multiple myeloma. AO-173 is an investigational CD47 targeting monoclonal antibody developed by Arch Oncology. Another, ALX Oncology has also received orphan drug designation for evorpacept for the treatment of patients with acute myeloid leukemia. The orphan drug designation is associated with incentives that favor the rapid approval of the drug in the region. Report Highlights: CD47 Inhibitor Drug Market Trends and Future Prospects Insight On More Than 50 CD47 Inhibitors Drugs In Clinical Trials Orphan, Fast Track, Breakthrough Therapy Designation Insight Insight On CD47 Inhibitors Drugs Biomarkers Sourced During Clinical Trials CD47 Inhibitors Drug Clinical Trials Insight By Company, Indication and Phase CD47 Inhibitors Drug Clinical Trials Insight As Mono and Combination Therapy Global CD47 Inhibitor Drug Market Dynamics Key Topics Covered: 1. CD 47 as Novel Cancer Immunotherapy Target 2. Ongoing Anti-CD47 Agents in Clinical Trials 2.1 CD47 Targeting Monoclonal Antibodies 2.2 CD47 Targeting Bispecific Antibodies 3. Current Market Trends & Future Prospects 4. Global CD47 Inhibitors Drug Clinical Pipeline Overview 4.1 By Country 4.2 By Company 4.3 By Indication 4.4 By Phase 5. Global CD47 Inhibitors Drug Clinical Pipeline By Company, Indication & Phase 5.1 Research 5.2 Preclinical 5.3 Phase-I 5.4 Phase-I/II 5.5 Phase-II 5.6 Phase-II/III 5.7 Phase-III 6. Global CD47 Inhibitor Drug Market Dynamics 6.1 Key Factors Driving CD47 Inhibitor Clinical Trials 6.2 Clinical & Technological Challenges 7. Competitive Landscape 7.1 Adagene 7.2 Alector 7.3 ALX Oncology 7.4 Beta Pharma 7.5 Biocad 7.6 ImmuneOncia Therapeutics 7.7 ImmuneOnco Biopharma 7.8 Light Chain Bioscience 7.9 Phanes Therapeutics 7.10 Virtuoso Therapeutics For more information about this report visit Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets